A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients

Kidney International

Volumn 73, Issue 7, 2008, Pages 856-862

  Kong, N C T ^a   Beran, J ^b,c   Kee, S A ^a   Miguel, J L ^d   Sanchez C ^d   Bayas, J M ^e   Vilella, A ^e   Calbo Torrecillas, F ^f   Lopez De Novales E ^f   Srinivasa, K ^g   Stoffel, M ^h   Hoet, B ^h  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b The Vaccination and Travel Medicine Center   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g GlaxoSmithKline Pharmaceuticals Ltd   (India)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant; Booster; FENDrix vaccine; Hemodialysis; Hepatitis B; Seroprotection

Indexed keywords

HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT;

EID: 40849130233     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002725     Document Type: Article

References (21)

1. Ribot S. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 1979; 139: 178-180.
2. Hollinger F. Factors influencing the immune response to hepatitis B vaccines. Booster dose guidelines and vaccine protocol recommendations. Am J Med 1989; 87(Suppl 3A): 36S-40S.
3. Eardley KS, Jones HE, Osman H et al. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant 2002; 17: 1982-1987.
4. Chow KM, Lau MC, Leung CB et al. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006; 103: c89-c93.
5. Quiroga JA, Castillo I, Porres JC et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12(4 Part 1): 661-663.
6. Kayataş M. Levamisole treatment enhances protective antibody response to hepatitis B vaccination in hemodialysis patients. Artif Organs 2002; 26: 492-496.
7. Fabrizi F, Dixit V, Martin P. Meta-analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther 2006; 23: 1559-1566.
8. Mauri JM, Vallés M, the Collaborative Group of Girona. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder chronic ureaemic patients. Neprol Dial Transplant 1997; 12: 729-732.
9. Fabrizin F, Andrulli S, Bacchini G et al. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204-1211.
10. Martin P, Friedman LS. Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995; 47: 1231-1241.
11. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2004; 79: 255-263.
12. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50(no. RR-5): 1-43.
13. Norella Kong CT, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005; 68: 2298-2303.
14. Impfempfehlungen der ständigen impfkommission (STIKO) an RKI. Epidemiologisches Bulletin Nr 2. Robert Koch Institut, Berlin, 2000.
15. Salisbury DM, Begg NT. Immunisation Against Infectious Disease. HM Stationery Office: London, 1996, pp 95-108.
16. Sezer S, Özdemir FN, Güz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant Proc 2000; 32: 607.
17. Navarro JF, Teruel JL, Mateos ML et al. antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95.
18. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355: 561-565.
19. Goffin E, Horsmans Y, Cornu C, Geubel A, Pirson Y. Acute hepatitis B infection after vaccination. Lancet 1995; 345: 261-263.
20. Jaiswal SB, Salgia PB, Sepaha AG, Chitnis DS. Hepatitis B vaccine in patients on haemodialysis. Lancet 1995; 346: 317-318.
21. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.